Notably, recent breakthroughs in migraine therapeutics have underscored how targeting neuropeptides, such as calcitonin-gene-related peptide, pituitary adenylate cyclase-activating polypeptide, and vasoactive intestinal polypeptide, can reshape our understanding of neuroinflammation and pain transmission, further emphasizing the need to develop quinoline-based agents with pleiotropic mechanisms [388]. The gene discussed is VIP; the disease is migraine disorder.